Alan Zloto, DO
Internal Medicine · Tampa, FLNPI 1770548273
Payments from drug & device makers
Across 309 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$751
- Amgen$618
- Lilly USA, LLC$555
- AstraZeneca$494
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$461
- Boehringer Ingelheim$439
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,43299%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $751 |
| Amgen | 39 | $618 |
| Lilly USA, LLC | 35 | $555 |
| AstraZeneca | 29 | $494 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $461 |
| Boehringer Ingelheim | 27 | $439 |
| Pfizer | 17 | $316 |
| Amarin Pharma, Inc. | 15 | $309 |
| Sanofi-aventis U.S. LLC | 12 | $260 |
| Johnson & Johnson | 11 | $221 |
| Bayer | 9 | $175 |
| AbbVie(2 entities) | 8 | $163 |
| Eisai Inc. | 7 | $132 |
| Novartis | 4 | $81 |
| Scilex Pharmaceuticals Inc. | 3 | $60 |
| GSK | 3 | $57 |
| Exact Sciences | 3 | $53 |
| Astellas Pharma US Inc | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 3 | $45 |
| Nevro Corp. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $19 |
| Medtronic | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
How this compares
$5,460 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $111,701 |
| EliquisApixaban | 68 | $69,272 |
| JardianceEmpagliflozin | 35 | $46,814 |
| XareltoRivaroxaban | 43 | $41,109 |
| FarxigaDapagliflozin Propanediol | 34 | $35,673 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $30,429 |
| MounjaroTirzepatide | 11 | $22,759 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $19,038 |
| JanuviaSitagliptin Phosphate | 22 | $17,623 |
| Repatha SureclickEvolocumab | 18 | $16,577 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $15,694 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $7,683 |
| DapagliflozinDapagliflozin Propanediol | 11 | $7,311 |
| Dexlansoprazole DrDexlansoprazole | 23 | $5,897 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $751 | $111,70163 claims |
| PfizerEliquis | $316 | $69,27268 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $439 | $60,12959 claims |
| Johnson & JohnsonXarelto | $221 | $41,10943 claims |
| AstraZenecaFarxiga | $494 | $35,67334 claims |
| Lilly USA, LLCMounjaro | $555 | $22,75911 claims |
| GSKTrelegy Ellipta | $57 | $19,03811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tampa
- Jhanelle GrayTampa$20.8M
- Sady AlpizarTampa$13.5M
- Karon LociceroTampa$6.6M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.